Simple improvements in vector design afford substantial gains in AAV delivery of aggregation-slowing Aβ variants
Adeno-associated virus (AAV) gene therapy for neurological disease has gained traction due to stunning advances in capsid evolution for CNS targeting. With AAV brain delivery now in focus, conventional improvements in viral expression vectors offer a complementary route for optimizing gene delivery....
Saved in:
Main Authors: | Ella Borgenheimer (Author), Cameron Trueblood (Author), Bryan L. Nguyen (Author), William R. Lagor (Author), Joanna L. Jankowsky (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
AAV gene therapy vectors in the TMJ
by: Sabine M. Brouxhon, et al.
Published: (2022) -
Rapamycin immune tolerization enables gene transfer following subcutaneous delivery of AAV6 but not CD4-retargeted AAV6 vectors in AAV-seropositive rhesus macaques
by: K. Jerome, et al.
Published: (2019) -
Immune responses to AAV vectors, from bench to bedside
by: Hildegard Buning
Published: (2015) -
Tissue-Dependent Expression and Translation of Circular RNAs with Recombinant AAV Vectors In Vivo
by: Rita M. Meganck, et al.
Published: (2018) -
AAV-vectored base editor trans-splicing delivers dystrophin repair
by: Zhen Li, et al.
Published: (2023)